C
Cirrus Therapeutics develops ocular immunology therapies targeting the full spectrum of dry age-related macular degeneration (AMD). The company utilizes AAV gene therapy to restore IRAK-M, aiming to slow disease progression by stabilizing upstream immune pathways. Additionally, a next-generation RPE cell therapy is in development to restore central vision for patients with advanced geographic atrophy.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Cirrus Therapeutics develops gene therapies targeting ocular immunology to treat dry Age-related Macular Degeneration (AMD). The company utilizes AAV vectors to restore IRAK-M protein levels, aiming to halt disease progression and potentially reverse vision loss. This approach rejuvenates the eye's natural defenses against inflammation and metabolic dysfunction associated with AMD.